An American Medical Association (AMA) Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code provides a distinct, alphanumeric identifier (e.g., 0123U) for proprietary clinical diagnostic laboratory tests (CDLTs) and advanced diagnostic laboratory tests (ADLTs). Offered on an accelerated quarterly schedule, PLA codes allow either a single performing clinical laboratory or an in vitro diagnostic (IVD) kit manufacturer to secure an assay-specific billing code without demonstrating the widespread national clinical adoption required for Category I CPT codes. However, securing a PLA code only establishes test identity; it does not confer reimbursement or clinical coverage. National Medicare pricing is determined independently through the Centers for Medicare & Medicaid Services (CMS) Clinical Laboratory Fee Schedule (CLFS) annual rate-setting process, where the test is evaluated for either crosswalking (benchmarking to an existing code) or gapfilling (contractor-level cost and pricing evaluation).
Key takeaways
- Dedicated Alphanumeric Structure: PLA codes consist of four numeric digits followed by the letter "U," published in the AMA CPT codebook to identify proprietary tests performed by a single laboratory or cleared/approved as an IVD kit [1].
- No Physician Work Component: Assays involving professional interpretations or physician work components (e.g., traditional surgical pathology) are ineligible; PLA codes apply strictly to technical laboratory procedures performed on human specimens [2].
- Rapid Quarterly Submission: Applications are submitted through the AMA CPT Smart App on a quarterly cycle, typically reaching active billing status within five to seven months of submission [3].
- Standardized Descriptors: AMA guidelines enforce a strict five-part nomenclature: target analytes, analytical methodology, specimen type, algorithmic calculation/result, and the test's proprietary trade name along with the performing entity [1].
- CLFS Payment Pathways: CMS establishes baseline Medicare rates under 42 CFR § 414.508 via crosswalking (direct comparison to existing codes) or gapfilling (a multi-stage contractor pricing review based on bench resources, commercial payer rates, and charges) [4].
- Coding Is Not Coverage: A PLA code does not guarantee coverage. In Medicare Administrative Contractor (MAC) jurisdictions participating in the Molecular Diagnostic Services (MolDx) program, laboratories must independently secure a DEX Z-Code and complete a technical assessment to obtain coverage.
Understanding AMA CPT PLA codes: structure and purpose
The AMA established the Proprietary Laboratory Analyses (PLA) section of the CPT code set to address the rapid pace of precision medicine and advanced molecular testing. Historically, novel molecular assays were billed using nonspecific unlisted codes (such as 81479 for unlisted molecular pathology) or by stacking multiple analyte-specific Category I codes. Both approaches introduce administrative friction, elevate audit scrutiny, and obscure the precise clinical technology being billed.
┌────────────────────────────────────────────────────────┐
│ Novel Molecular Diagnostic │
└───────────────────────────┬────────────────────────────┘
│
Does the assay have broad, multi-center
national clinical adoption & data?
│
┌────────────────┴────────────────┐
▼ NO ▼ YES
┌────────────────────────┐ ┌────────────────────────┐
│ AMA CPT PLA │ │ Category I CPT Code │
│ Application Route │ │ Application Route │
│ • Quarterly cycle │ │ • Annual / Triannual │
│ • Single-lab or kit │ │ • Broad literature │
│ • 4 digits + "U" │ │ • Multi-lab adoption │
└────────────────────────┘ └────────────────────────┘
A PLA code is an alphanumeric identifier comprising four digits followed by the suffix "U" (e.g., 0001U through 9999U) [1]. These codes are published quarterly on the AMA CPT PLA Codes portal and integrated into the annual CPT codebook [1].
A PLA code is tied specifically to the performing laboratory or kit manufacturer and the proprietary trade name of the assay [1]. While a standard Category I CPT code is generic—describing a methodology that any qualified laboratory can execute—a PLA code identifies an exact proprietary diagnostic product [1].
PLA vs. Category I CPT vs. unlisted codes
Choosing between a PLA code, a Category I code, or an unlisted code depends on the test's commercial status, analytical composition, and clinical adoption profile.
| Parameter | CPT Category I Code | AMA CPT PLA Code (####U) | Unlisted Code (e.g., 81479) |
|---|---|---|---|
| Typical Target | Generic, widely adopted assays | Proprietary tests or IVD test kits | Assays lacking any specific code |
| Applicant Eligibility | Any stakeholder / medical specialty society | Single performing lab or IVD kit manufacturer [1, 2] | N/A (Default billing code) |
| Utilization Requirement | Broad national utilization across multiple centers | No national adoption threshold; single-site utilization accepted | None |
| Peer-Reviewed Evidence | Extensive independent multi-center literature | Evidence demonstrating analytical validity and clinical relevance | Evaluated on individual claim basis |
| Application Cadence | Three meetings annually; annual publication | Four quarterly cycles per year [3] | Immediate (No application needed) |
| Time to Activation | 12 to 24 months | 5 to 7 months [3] | Immediate |
| Payer Adjudication | Automated based on established coverage policies | Automated once coded, priced, and covered | Manual claim-by-claim review; high denial rates |
While unlisted codes require no application, they routinely trigger manual claims processing, demands for clinical notes, and payment delays. Conversely, Category I codes carry strict evidentiary thresholds that early-commercialization diagnostic developers often cannot meet. The PLA pathway provides an accessible, formal coding mechanism for proprietary innovations. Laboratories navigating this procedural transition can leverage strategic documentation and coding support through CPT and PLA coding services.
Eligibility criteria for a PLA code application
The AMA Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG) and the CPT Editorial Panel maintain rigorous eligibility requirements for PLA code applicants [1]. Failure to satisfy any single criterion results in application rejection or administrative postponement.
1. Eligible applicant entity
The application must be submitted by either [1, 2]:
- The single clinical laboratory that developed and performs the proprietary assay (as a laboratory-developed test, or LDT, validated under CLIA), or
- The commercial manufacturer of an FDA-cleared or FDA-approved in vitro diagnostic (IVD) kit distributed to multiple laboratories.
If multiple independent laboratories perform the same LDT using their own disparate protocols, they are ineligible for a single shared PLA code. Each laboratory must apply independently, or an existing Category I code must be used [2].
2. Human specimen requirement
The diagnostic procedure must be performed exclusively on human specimens (e.g., peripheral blood, plasma, bone marrow, formal-fixed paraffin-embedded [FFPE] tissue, urine, cerebrospinal fluid, or saliva) for clinical healthcare purposes [1, 2]. Assays designed for environmental, veterinary, or non-clinical research use are excluded.
3. Exclusion of physician work components
PLA codes are strictly technical laboratory procedures [2]. They cannot include a professional physician work component (such as an interpretation and report that involves physician-level diagnostic work, typical of anatomic pathology codes) [2]. If an assay relies on a pathologist or physician interpretation that is separately reportable under Medicare rules, it cannot be packaged into a PLA code descriptor [2].
4. Regulatory and commercial transparency
The applicant must declare the regulatory status of the assay in the submission portal:
- CLIA-certified laboratory-developed test (LDT),
- FDA 510(k) clearance,
- Premarket Approval (PMA), or
- De Novo classification.
The test must be commercially available or actively clinical-grade at the time of application or slated for immediate availability upon code publication [2].
Descriptor architecture: crafting an AMA-compliant descriptor
The AMA mandates a uniform, five-part nomenclature standard for all PLA procedure descriptors [1]. The descriptor must convey the technical essence of the test without incorporating promotional or hyperbolic marketing language.
┌────────────────────────────────────────────────────────────────────────────────┐
│ AMA PLA Procedure Descriptor Structure │
├─────────────────┬──────────────────┬──────────────┬───────────────┬────────────┤
│ 1. Analytes │ 2. Methodology │ 3. Specimen │ 4. Algorithmic│ 5. Trade │
│ or Targets │ │ Source │ Calculation│ Name & │
│ │ │ │ or Result │ Entity │
└─────────────────┴──────────────────┴──────────────┴───────────────┴────────────┘
- Analytes / Biomarkers: The specific biological targets measured. This may be a quantitative count of genes, microRNAs, proteins, methylated regions, circulating tumor cells, or microbial species (e.g., "Oncology (colorectal), mRNA, gene expression profiling of 12 genes").
- Analytical Methodology: The primary laboratory technology employed to generate the raw data. Examples include next-generation sequencing (NGS), reverse-transcription quantitative PCR (RT-qPCR), liquid chromatography–tandem mass spectrometry (LC-MS/MS), or bead-based multiplex immunoassay.
- Specimen Source: The biological matrix required for testing (e.g., "plasma," "formalin-fixed paraffin-embedded (FFPE) tissue," "whole blood," or "clean-catch urine").
- Algorithmic Calculation or Clinical Output: If the test yields an algorithmically derived risk score, proprietary index, or binary predictive result, this must be explicitly detailed (e.g., "utilizing formal statistical modeling, reported as a categorical risk score for disease recurrence"). If the test reports simple quantitative values without an algorithm, this element reflects standard reporting.
- Proprietary Trade Name and Performing Facility: The final, parenthetical section of the descriptor identifies the proprietary commercial name of the test alongside the legal corporate name of the performing laboratory or kit manufacturer (e.g., "TestTradeName®, Performing Laboratory Name, Laboratory Inc.") [1].
Drafting an overly broad descriptor will trigger immediate technical revisions from the PLA-TAG. Conversely, an excessively narrow descriptor may require premature re-application if slight improvements to the internal assay design occur.
The quarterly application cycle and implementation timeline
PLA code applications are managed exclusively through the digital AMA CPT Smart App portal [3]. The AMA processes submissions on four strict quarterly cycles each calendar year [3].
Cycle Deadline PLA-TAG Review & CPT Panel Action AMA Web Release Effective Date
(Smart App) Public Comments (Approve/Reject) (Data Files) (Billing Active)
│ │ │ │ │
▼ ▼ ▼ ▼ ▼
┌─────────┐ ┌─────────┐ ┌─────────┐ ┌─────────┐ ┌─────────┐
│ Month 0 │ ──1-2 mos──► │ Month 2 │ ───1-2 mos──► │ Month 3 │ ────1 mo─────► │ Month 4 │ ───3 mos───►│ Month 7 │
└─────────┘ └─────────┘ └─────────┘ └─────────┘ └─────────┘
The quarterly milestone phases
The progression from initial digital submission to operational billing follows five continuous steps:
- Application Submission: The applicant uploads the complete protocol, analytical validation summary, commercial collateral, and proposed descriptor before the published cycle deadline (typically in January, April, July, or October) [3]. Administrative staff screen submissions for completeness; applicants typically receive two business days to rectify minor omissions.
- Public Comment & PLA-TAG Review: The proposed descriptor is posted for public scrutiny. The Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG)—composed of laboratory experts, molecular pathologists, and coding authorities—evaluates the technical merits and standardizes the descriptor language.
- CPT Editorial Panel Adjudication: The CPT Editorial Panel reviews the PLA-TAG recommendation during its subsequent executive session. The Panel issues one of four formal determinations: Approve, Approve with Modification, Reject, or Postpone.
- Electronic Publication: Approved codes, along with their long, medium, and short descriptors, are published on the AMA website approximately one to two months after the Panel meeting [3].
- Commercial Implementation (Effective Date): Codes become active for clinical claim submission roughly three months following electronic publication (aligned to January 1, April 1, July 1, or October 1) [3]. This window gives commercial payers, clearinghouses, and electronic health record (EHR) systems time to load the new alphanumeric codes into their claim engines.
Missing a quarterly cutoff pushes the application to the subsequent cycle, postponing billing enablement by a minimum of 90 days.
Medicare CLFS pricing pathways: crosswalk vs. gapfill
Securing an AMA PLA code establishes procedure identity, but leaves payment undetermined. Medicare pricing for clinical laboratory procedures is governed by Section 1834A of the Social Security Act and detailed under 42 CFR § 414.508 [4].
Each summer, CMS hosts the Annual Clinical Laboratory Fee Schedule (CLFS) Public Meeting, where newly approved CPT and PLA codes are evaluated for pricing via one of two statutory mechanisms: crosswalking or gapfilling [4].
Approved AMA PLA Code
│
▼
CMS Annual CLFS Public Meeting
(Summer Review: June/July)
│
┌──────────────────────┴──────────────────────┐
▼ ▼
Pathway 1: Crosswalk Pathway 2: Gapfill
• Comparable to existing code • No comparable code exists
• Direct, partial, or bundled • 1-year contractor (MAC) review
• Price active: January 1 • Pricing inputs: costs, charges,
commercial rates
• Median sets National Limitation
Amount (NLA)
Pathway 1: Crosswalking
Crosswalking is applied when a newly coded test is analytically, technologically, and resource-wise comparable to an existing test already priced on the CLFS [4].
- Mechanics: The reimbursement rate is established by linking the new code to an existing CPT code (1:1 crosswalk), a combination of existing codes, or a benchmarked fraction of a code [4].
- CMS Scrutiny: Historically, CMS has been skeptical of additive or fractional crosswalk recommendations that multiply rates without clear evidence of proportional bench work.
- Advantage & Timeline: If CMS and the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (CDLT Panel) accept a crosswalk recommendation, the assigned rate takes effect on January 1 immediately following the summer public meeting [4]. This eliminates pricing uncertainty and expedites commercial reimbursement.
Pathway 2: Gapfilling
Gapfilling is applied when no existing CPT code sufficiently approximates the technological platform, laboratory instrumentation, molecular complexity, or reagents used in the new assay [4]. This is the standard outcome for novel multi-analyte assays with algorithmic analyses (MAAAs), comprehensive liquid biopsy panels, and complex transcriptomic profiles.
When CMS elects to gapfill a code, it defers rate setting to the local Medicare Administrative Contractors (MACs) for a one-year evaluation period [4]. Under 42 CFR § 414.508, MACs establish interim pricing based on four concrete inputs [4]:
- Laboratory Resource Expenditures: The documented direct bench costs to perform the test, including laboratory personnel time, assay reagents, proprietary consumables, and instrumentation capital depreciation.
- Laboratory Charges: The gross list price (charge master) set by the performing laboratory.
- Commercial Payer Payments: Historical and current allowable payment rates negotiated with private commercial insurance carriers.
- Pricing of Comparable Tests: Regional contractor data on related diagnostic services.
The Gapfill timeline
During the gapfill year, local MACs issue preliminary pricing determinations in the spring (typically April or May) [4]. Following a 60-day public comment period, MACs release final contractor-level pricing in late summer [4].
CMS calculates the national rate by taking the median of all local MAC determinations to establish the National Limitation Amount (NLA) [4]. That final NLA takes effect on January 1 of the subsequent calendar year [4]. During the interim gapfill year, laboratories submit claims to their local MAC, which adjudicates payments based on its individual local determination.
The triad of commercialization: coding, pricing, and coverage
Diagnostic innovators often mistakenly assume that receiving an approved PLA code with an established CLFS price ensures clinical reimbursement. In US healthcare reimbursement, market access requires three distinct, independently managed operational pillars:
┌──────────────────────────────────────────────┐
│ Diagnostic Commercialization │
└──────────────────────┬───────────────────────┘
│
┌────────────────────────────┼────────────────────────────┐
▼ ▼ ▼
1. Identity 2. Valuation 3. Medical Necessity
AMA PLA Code CMS CLFS Pricing MAC & Payer Coverage
• Establishes alphanumeric • Sets national ceiling • Local Coverage
code (0123U) via Crosswalk or Determinations (LCD)
• Defines methodology Gapfill (42 CFR § 414.508) • DEX Z-Code registration
• Quarterly cadence • Annual CMS cycle • Technical Assessment
- Coding (AMA): Defines what the test is. It assigns a clear alphanumeric identifier to standardize claims routing [1].
- Pricing (CMS / Payers): Defines how much the test is valued at, established nationally via the CLFS crosswalk or gapfill pathways [4].
- Coverage (MACs / Commercial Payers): Defines why and for whom the test will be paid, based on clinical utility, medical necessity, and clinical validity.
In the 28+ states governed by Medicare Administrative Contractors operating under the MolDx program (including Palmetto GBA, Noridian, CGS, and NGS), a laboratory billing an approved PLA code will face claim denials unless the test also holds an active DEX Z-Code and an approved MolDx Technical Assessment (TA). The TA evaluates analytical and clinical validity alongside clinical utility to establish coverage under a specific Local Coverage Determination (LCD). Navigating this dossier submission and registration process requires meticulous preparation, as outlined in technical guides to the MolDx technical assessment process.
Understanding the boundaries of each pillar allows diagnostic developers to run coding applications, cost accounting analyses, and clinical utility studies concurrently, avoiding commercialization bottlenecks.
How Priestly Consulting can help
Priestly Consulting provides strategic reimbursement, coding, and technical documentation advisory services to clinical laboratories, molecular diagnostic developers, and biotechnology innovators navigating diagnostic commercialization. Our services include:
- Developing defensible AMA CPT PLA code applications, including technical descriptor drafting aligned with AMA nomenclature standards.
- Formulating CLFS pricing strategies, evaluating crosswalk feasibility, and compiling contractor-level cost accounting dossiers for the Medicare gapfill process.
- Aligning coding submissions with analytical validation documentation, DEX Z-Code registrations, and MolDx Technical Assessments.
Disclaimer: Priestly Consulting provides scientific, technical, and regulatory documentation strategy. We are not a clinical testing laboratory, and our advisory services do not constitute legal or formal financial advice, nor do they guarantee CPT code approval, Medicare coverage, or third-party reimbursement.
To discuss your molecular assay commercialization and coding roadmap, schedule a consultation.
References
- American Medical Association. CPT® Proprietary Laboratory Analyses (PLA) Codes. Available from: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes [Accessed October 2026].
- American Medical Association. CPT® PLA Codes Frequently Asked Questions (FAQs). Available from: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes-faq [Accessed October 2026].
- American Medical Association. CPT® PLA Calendar of Key Dates & Deadlines. Available from: https://www.ama-assn.org/practice-management/cpt/cpt-pla-calendar [Accessed October 2026].
- Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule (CLFS) Annual Public Meetings & 42 CFR § 414.508 Payment Bases. Available from: https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings [Accessed October 2026].
